Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy (PRA)

October 4, 2017 updated by: Kyu Eun Lee, Seoul National University Hospital

Randomized Controlled Trial Between PRA(Posterior Retroperitoneoscopic Adrenalectomy) and LA(Laparoscopic Adrenalectomy)

The purpose of this study is to compare two surgical methods of adrenalectomy. One is called PRA(posterior retroperitoneal adrenalectomy), which is performed through 3 or 4 holes at patient's back. The other is LA(laparoscopic adrenalectomy) which is performed through patient's abdominal cavity after making 3 or 4 holes in the abdomen.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Since 1992, transabdominal LA(laparoscopic adrenalectomy) has been a standard method of adrenalectomy. This traditional method has been used widely because this procedure provides wide view of the whole abdomen which is familiar to surgeons. But due to its unique location at retroperitoneum, adrenal is still not easy to approach. So various retroperitoneal approaches were designed and adjusted. Among those, PRA(posterior retroperitoneal adrenalectomy) has showed good outcomes in many institutes. PRA facilitates direct approach to kidney and adrenal gland, and so operative time can be shortened. But there has been no randomized controlled trial between these two methods.

Therefore, as experienced surgeons in both methods, we want to practice this study.

Study Type

Interventional

Enrollment (Actual)

83

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 77 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients who are expected to have benign adrenal disease at preoperative exams
  • Patients who have pheochromocytoma measured less than 5cm, and the other benign adrenal tumors less than 7cm in diameter in preoperative CT scan
  • Patients who do not have previous surgery history at the interested quadrant
  • Patients who is I or II grade in ASA classification(American society of anesthesiologists' physical status classification)
  • Patients who has tolerable liver function and renal function(bilirubin<2.0mg/dl and AST, ALT, serum creatinine within twice of upper normal range, coagulation panel : within normal limit)
  • Patients whose BMI(body mass index) is less than 35
  • Patients who are supposed to have normal cognitive function
  • Patients who signed the consent paper.

Exclusion Criteria:

  • Patients who are expected to have malignant or metastatic adrenal tumor at preoperative exams
  • Patients who have bilateral adrenal tumors
  • Patients who have condition to undergo the other operation at the abdomen together with adrenalectomy
  • Pregnant patients
  • Patients who have active or uncontrolled infection
  • Patients who have medical problems as below
  • Uncontrollable hypertension with medication(Systolic BP>150 or diastolic BP>100)
  • Angina, congestive heart failure, acute myocardial infection
  • History of coronary angioplasty or Coronary artery bypass graft surgery
  • History of stroke, transient ischemic attack with sequela

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PRA
Persons who get PRA surgery.
Experimental: LA
Persons who get LA surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Operation time
Time Frame: Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
operation time will be measured by attending nerse
Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain sensation after surgery
Time Frame: Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Pain score will be described daily during hospitalization, and also at out patient clinic after discharge
Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Recovery of bowel movement
Time Frame: Participants will be followed the duration of hospital stay, an expected average of 5 days
Gas out is regarded as a recovery of bowel movement
Participants will be followed the duration of hospital stay, an expected average of 5 days
Wound complication
Time Frame: Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Blood loss during operation
Time Frame: Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Intra-operative hemodynamic status
Time Frame: Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks
Events as below will be recorded and compared severe hypertension(systolic BP>200mmHg), severe hypotension(systolic BP<90mmHg), Tachycardia(HR>110/min), Bradycardia(HR<50/min)
Participants will be followed until the first visit of out patients clinic after discharge, an expected average of 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kyueun Lee, Ph.D, Seoul National University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2012

Primary Completion (Actual)

February 28, 2016

Study Completion (Actual)

February 28, 2016

Study Registration Dates

First Submitted

August 22, 2012

First Submitted That Met QC Criteria

August 27, 2012

First Posted (Estimate)

August 30, 2012

Study Record Updates

Last Update Posted (Actual)

October 6, 2017

Last Update Submitted That Met QC Criteria

October 4, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Kyu.eun.lee-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adrenal Disease

Clinical Trials on PRA

3
Subscribe